- Home
- INMB vs BSEM Comparison
INMB vs BSEM Comparison
Compare INMB & BSEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | BSEM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 76.9M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | INMB | BSEM |
|---|---|---|
| Price | $1.62 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 295.4K | 129.6K |
| Earning Date | 11-02-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $1.66 |
| 52 Week High | $2.60 | $5.44 |
Technical Indicators
Market Signals| Indicator | INMB | BSEM |
|---|---|---|
| Relative Strength Index (RSI) | 27.80 | 25.00 |
| Support Level | $1.36 | N/A |
| Resistance Level | $1.76 | $4.12 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 2.92 | 0.00 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About BSEM BioStem Technologies Inc. Common Stock
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.